ATX‑011 / Alethio Therapeutics - LARVOL DELTA

Alethio Therapeutics…announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. (GlobeNewswire) - "Alongside this, the Company announces the appointment of Steve R. Coats...to advance the ATX-011 programme towards IND submission, targeted for Q1 2027....Rapid path to PoC: targeting H1 2028 for clinical proof‑of‑concept data, following a Q1 2027 IND."

Clinical data • IND • New molecule • Essential Thrombocythemia